Ticker > Company >

Lyka Labs share price

Lyka Labs Ltd.

NSE: LYKALABS BSE: 500259 SECTOR: Pharmaceuticals & Drugs  40.88 K   76   5

109.90
-0.65 (-0.59%)
BSE: 14 Jul 04:01 PM

Price Summary

Today's High

₹ 110.75

Today's Low

₹ 107.5

52 Week High

₹ 175.95

52 Week Low

₹ 90.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

392.23 Cr.

Enterprise Value

428.91 Cr.

No. of Shares

3.57 Cr.

P/E

47.67

P/B

2.91

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  37.81

CASH

1.32 Cr.

DEBT

38 Cr.

Promoter Holding

58.16 %

EPS (TTM)

₹  2.31

Sales Growth

26.6%

ROE

7.31 %

ROCE

8.38%

Profit Growth

462.59 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year26.6%
3 Year-6.42%
5 Year27.02%

Profit Growth

1 Year462.59%
3 Year-40.92%
5 Year16.53%

ROE%

1 Year7.31%
3 Year-7.14%
5 Year3.45%

ROCE %

1 Year8.38%
3 Year3.3%
5 Year12.32%

Debt/Equity

0.2816

Price to Cash Flow

119.88

Interest Cover Ratio

5.9793

CFO/PAT (5 Yr. Avg.)

5.27303339773668

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 58.16 0.00
Mar 2025 58.16 0.00
Dec 2024 58.10 0.00
Sep 2024 58.10 0.00
Jun 2024 58.10 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 18.7041 Cr.
  • The Company has been maintaining an effective average operating margins of 25.763274930163% in the last 5 years.
  • Company’s PEG ratio is 0.109291516456937.
  • The company has an efficient Cash Conversion Cycle of 34.6815 days.
  • The company has a good cash flow management; CFO/PAT stands at 5.27303339773668.
  • The company has a high promoter holding of 58.16%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.37876733855405.

 Limitations

  • The company has shown a poor profit growth of -40.9230532401072% for the Past 3 years.
  • The company has shown a poor revenue growth of -6.41680968686604% for the Past 3 years.
  • Company has a poor ROE of -7.1422% over the past 3 years.
  • Company has a poor ROCE of 3.30006666666667% over the past 3 years
  • The company is trading at a high PE of 47.67.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 26.98 30.11 41.16 32.92 30.52
Total Expenditure 24.77 26.05 35.82 27.84 27.11
Operating Profit 2.22 4.06 5.34 5.09 3.41
Other Income 0.39 0.62 0.13 0.87 0.72
Interest 1.04 0.65 0.52 0.62 0.52
Depreciation 2.77 1.68 1.68 1.75 1.34
Exceptional Items -0.01 0 0 0 0
Profit Before Tax -1.21 2.35 3.27 3.59 2.27
Tax 0.41 0.6 0.8 0.89 0.97
Profit After Tax -1.62 1.75 2.47 2.7 1.31
Adjusted EPS (Rs) -0.49 0.49 0.69 0.76 0.37

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 62.26 164.35 80.59 106.4 134.7
Total Expenditure 47.84 66.85 64.99 91.84 116.81
Operating Profit 14.43 97.5 15.6 14.56 17.89
Other Income 2.21 2.72 3.45 1.65 2.34
Interest 25.55 19.92 11.57 4.8 2.3
Depreciation 8.05 15.39 13.52 12.29 6.45
Exceptional Items -1.43 -4.67 -7.17 -0.06 0
Profit Before Tax -18.4 60.24 -13.21 -0.93 11.47
Tax -3.94 20.34 0.08 1.34 3.25
Net Profit -14.46 39.9 -13.29 -2.27 8.23
Adjusted EPS (Rs.) -5.04 13.91 -4.33 -0.69 2.31

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 28.69 28.69 30.69 33.09 35.69
Total Reserves -24.28 15.75 45.74 66.24 99.25
Borrowings 151.06 61.63 63.4 42.91 19.21
Other N/C liabilities -3.71 8.77 9.06 7.87 6.65
Current liabilities 45.39 93.68 29.97 35.91 44.78
Total Liabilities 197.15 208.51 178.86 186.02 205.58
Assets
Net Block 95.34 90.11 65.53 55.64 84.44
Capital WIP 16.18 16.23 15.1 21.97 0.2
Intangible WIP 8.22 1.51 1.12 1.08 1
Investments 32.4 32.4 32.4 32.4 32.4
Loans & Advances 19.28 21.06 22.41 25.05 21.42
Other N/C Assets 0 0 0 0 0
Current Assets 25.74 47.19 42.3 49.86 66.12
Total Assets 197.15 208.51 178.86 186.02 205.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -18.4 60.24 -13.21 -0.93 11.47
Adjustment 33.97 37.6 31.31 16.66 8.44
Changes in Assets & Liabilities -9.1 -20.76 -10.81 -11.16 -13.66
Tax Paid -0.72 -0.55 -0.41 -1.47 -2.98
Operating Cash Flow 5.75 76.53 6.87 3.09 3.27
Investing Cash Flow 0.13 -4.33 6.77 -8.61 -13.1
Financing Cash Flow -7.75 -63.35 -20.33 2.71 5.26
Net Cash Flow -1.88 8.85 -6.69 -2.81 -4.57

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 58.10 58.10 58.10 58.16 58.16
alisha kunal gandhi - - - 0.13 0.13
bhawna godha 0.02 0.02 0.02 0.02 0.02
enai trading and investme... 2.80 2.80 2.80 2.80 2.80
ipca laboratories limited... 40.98 40.98 40.98 40.98 40.98
kunal narendra gandhi 6.79 6.79 6.79 9.79 9.79
lyka generics limited 0.06 0.06 0.06 0.06 0.06
neetu godha 0.03 0.03 0.03 0.03 0.03
nehal narendra gandhi 6.53 6.53 6.53 3.46 3.26
pranay godha 0.84 0.84 0.84 0.84 0.84
premchand godha 0.03 0.03 0.03 0.03 0.03
sweta shah - - - - 0.11
usha godha - - - - 0.03
ushma ronak shah - - - - 0.09
usha premchand godha 0.03 0.03 0.03 0.03 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 41.90 41.90 41.90 41.84 41.84
dalal & broacha stock bro... - - - 1.12 1.12
llp 0.62 0.63 0.64 0.85 0.87
thermo capital private li... - - - 1.55 1.53
thermo pads private limit... 2.29 1.76 1.41 - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2023
Annual Report 2023
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INDIA RATINGS
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Lyka Labs - Quaterly Results 26 May, 6:44 PM Lyka Labs - Quaterly Results 26 May, 6:44 PM Lyka Labs gets Indian patent for Pregabalin Gel 8% 8 Apr, 2:42 PM Lyka Labs informs about press release 8 Apr, 2:17 PM Lyka Labs informs about certificate 4 Apr, 4:52 PM Lyka Lab informs about voting results and scrutinizer’s report 5 Mar, 5:13 PM Lyka Labs informs about integrated filing 5 Feb, 3:53 PM Lyka Labs informs about outcome of board meeting 4 Feb, 5:09 PM Lyka Labs - Quaterly Results 4 Feb, 3:11 PM Lyka Labs - Quaterly Results 4 Feb, 3:11 PM Lyka Labs - Quaterly Results 4 Feb, 3:11 PM Lyka Labs informs about scheme of amalgamation 24 Jan, 3:02 PM Lyka Labs informs about board meeting 30 Dec, 5:16 PM Lyka Labs - Quaterly Results 12 Nov, 12:55 PM Lyka Labs - Quaterly Results 12 Nov, 12:55 PM Lyka Labs informs about scheme of amalgamation 26 Oct, 12:54 PM Lyka Labs informs about board meeting 4 Oct, 12:40 PM Lyka Labs informs about newspaper advertisement 12 Aug, 12:26 PM Lyka Labs - Quaterly Results 9 Aug, 1:31 PM Lyka Labs - Quaterly Results 9 Aug, 1:31 PM Lyka Labs - Quaterly Results 9 Aug, 1:31 PM Lyka Labs informs about newspaper publication of AGM 18 Jul, 2:40 PM Lyka Labs informs about press release 16 Jul, 5:30 PM Lyka Labs informs about details of loss of certificate 26 Jun, 2:12 PM Lyka Labs - Quaterly Results 21 May, 5:47 PM Lyka Labs - Quaterly Results 21 May, 5:47 PM Lyka Labs informs about change in time of board meeting 14 May, 10:39 AM Lyka Labs informs about board meeting 10 May, 2:47 PM Lyka Labs informs about disclosure 18 Apr, 3:35 PM Lyka Labs - Quaterly Results 8 Feb, 1:44 PM Lyka Labs - Quaterly Results 8 Feb, 1:44 PM Lyka Labs - Quaterly Results 8 Feb, 1:44 PM Lyka Labs informs about change in directorate 16 Jan, 3:12 PM Lyka Labs informs about loss of share certificates 3 Jan, 2:21 PM Lyka Labs informs about issuance of duplicate share certificates 1 Dec, 3:21 PM Lyka Labs informs about update on scheme of amalgamation 25 Nov, 3:20 PM Lyka Labs - Quaterly Results 2 Nov, 1:56 PM Lyka Labs - Quaterly Results 2 Nov, 1:56 PM Lyka Labs - Quaterly Results 2 Nov, 1:56 PM Lyka Labs informs about disclosure 10 Oct, 4:20 PM Lyka Labs gets product permission from CDSCO for Tofacitinib Ointment 10 Oct, 12:11 PM Lyka Labs informs about change in directorate 27 Sep, 4:41 PM Lyka Lab informs about issuance of duplicate share certificate 26 Sep, 2:25 PM Lyka Labs informs about details of loss of certificate 24 Aug, 5:05 PM Lyka Labs informs about loss of share certificates 21 Aug, 5:18 PM Lyka Labs informs about voting results and scrutinizer report 3 Aug, 1:19 PM Lyka Labs - Quaterly Results 2 Aug, 2:11 PM Lyka Labs - Quaterly Results 2 Aug, 2:11 PM Lyka Labs - Quaterly Results 2 Aug, 2:11 PM Lyka Labs informs about details of loss of certificate 26 Jun, 2:57 PM

Lyka Labs Stock Price Analysis and Quick Research Report. Is Lyka Labs an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lyka Labs and its performance over the period of time. Lyka Labs stock price today is Rs 110.1.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Lyka Labs cash from the operating activity was Rs 3.272 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lyka Labs has a Debt to Equity ratio of 0.2816 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lyka Labs , the EPS growth was 436.182 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lyka Labs has OPM of 13.2807314766283 % which is a bad sign for profitability.
     
  • ROE: Lyka Labs have a poor ROE of 7.3065 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Lyka Labs is Rs 110.1. One can use valuation calculators of ticker to know if Lyka Labs share price is undervalued or overvalued.
Last Updated on:
Brief about Lyka Labs
X